e-learning
resources
Stockholm 2002
Sunday 15.09.2002
Prevalence and costs of COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The cost of COPD: results from the SIRIBO study
L. G. Mantovani, S. Mannino, C. F. Donner, R. M. Busca, M. C. J. M. Sturkenboom (Milan, Segrate, Verona, Italy; Rotterdam, The Netherlands)
Source:
Annual Congress 2002 - Prevalence and costs of COPD
Session:
Prevalence and costs of COPD
Session type:
Thematic Poster Session
Number:
832
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. G. Mantovani, S. Mannino, C. F. Donner, R. M. Busca, M. C. J. M. Sturkenboom (Milan, Segrate, Verona, Italy; Rotterdam, The Netherlands). The cost of COPD: results from the SIRIBO study. Eur Respir J 2002; 20: Suppl. 38, 832
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Risk factors of adverse outcome after acute hospitalization in Idiopathic Pulmonary Fibrosis (IPF)
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Direct cost analysis of COPD patients: A 1 year follow-up study
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Characteristics of COPD patients with repeated exacerbations: preliminary results from the PRE-SPIRO survey
Source: Annual Congress 2008 - COPD epidemiology
Year: 2008
GOLD classification of COPD and subsequent mortality: findings from a cohort study
Source: Annual Congress 2004 - Burden of obstructive lung diseases: costs, mortality and life impairment
Year: 2004
Real-world exacerbation rates in Japanese patients with COPD: results from the EXACOS observational cohort study
Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations
Year: 2021
The cost analysis of our COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 38s
Year: 2006
The Spanish national clinical audit on COPD exacerbations. Results of a pilot study: main outcomes
Source: Annual Congress 2008 - Prognosis in COPD
Year: 2008
Persistence to COPD therapies and impact on exacerbations: a French claims data study
Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections
Year: 2018
The Spanish national clinical audit on COPD exacerbations. results of a pilot study: spirometry outcomes
Source: Annual Congress 2008 - Organisation of care and management of COPD
Year: 2008
Preliminary results of relationship between appetite and clinical presentation of COPD patients in AERIS study
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Efficacy of tiotropium/olodaterol on sedentary/active time in COPD patients: VESUTO study
Source: International Congress 2018 – COPD management
Year: 2018
DuoResp Spiromax adherence, satisfaction and ease of use: findings from a multi-country observational study in patients with asthma and COPD (SPRINT)
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018
The long-term clinical and economic impact of COPD exacerbations: an observational study (SHERLOCK)
Source: Virtual Congress 2020 – Prediction and management of outcomes in obstructive diseases
Year: 2020
Worldwide under-diagnosis of COPD: results from the bold study
Source: Annual Congress 2009 - Methodological aspects of asthma and COPD epidemiology
Year: 2009
A prediction model for exacerbations in patients with COPD generated in a Swiss multicenter COPD cohort study (TOPDOCS)
Source: International Congress 2017 – Primary care management of asthma and COPD
Year: 2017
NIV after acute exacerbation of COPD: results from the Dutch multicentre study
Source: International Congress 2015 – Long-term non-invasive ventilation (NIV) in COPD
Year: 2015
Real-life COPD patients compared to large trial populations: An UNLOCK external validity study
Source: Annual Congress 2013 –Management of respiratory diseases in primary care
Year: 2013
Statins and mortality in COPD in the COMIC study: A prospective COPD cohort study
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
The impact of comorbidities on mortality in COPD, report from the OLIN COPD study.
Source: International Congress 2018 – Respiratory epidemiology: from COPD to factors that associate with lung function and infections
Year: 2018
Prevalence of COPD: updated meta-analysis results
Source: Annual Congress 2007 - Environmental and clinical aspects of COPD
Year: 2007
The Spanish national clinical audit on COPD exacerbations (eCOPD). Pilot study: selection of study subjects
Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept